Statements (70)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Acquired by a larger pharmaceutical company
|
| gptkbp:advertising |
focused on niche oncology markets
|
| gptkbp:businessModel |
biopharmaceutical development
expanding market reach. |
| gptkbp:clinicalTrials |
ongoing
Phase 2 CB-839 published in scientific journals utilizes cutting-edge technology achieved significant progress aims to identify novel compounds focused on solid tumors located in multiple regions includes_Phase_1_and_Phase_2 |
| gptkbp:collaborations |
academic institutions
with biotech firms with leading cancer research centers with research hospitals |
| gptkbp:community_engagement |
involved in cancer awareness programs
|
| gptkbp:community_outreach |
supports local cancer initiatives
|
| gptkbp:community_service |
focused on efficacy and safety
engages with cancer support groups |
| gptkbp:competitors |
conducted for strategic planning
|
| gptkbp:drugInterdiction |
monitored throughout development
small molecule inhibitor targeting various cancer pathways |
| gptkbp:employees |
growing team of scientists and professionals
|
| gptkbp:enrollment |
targeting specific cancer types
|
| gptkbp:feedback |
measured in trials
|
| gptkbp:financialPerformance |
reported quarterly earnings
monitored by investors |
| gptkbp:focus |
cancer therapeutics
|
| gptkbp:founded |
2010
|
| gptkbp:founder |
Susan_M._Molineaux
|
| gptkbp:funding |
from public offerings
secured from grants and investments sourced from various investors |
| gptkbp:future_plans |
expanding drug pipeline
|
| gptkbp:governance |
adheres to best practices
|
| gptkbp:headquarters |
gptkb:San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Calithera Biosciences
|
| gptkbp:investmentFocus |
Venture capital firms
provides updates to shareholders |
| gptkbp:leadership |
experienced management team
|
| gptkbp:market |
oncology drugs
|
| gptkbp:mission |
to improve cancer treatment outcomes
|
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
with pharmaceutical companies with healthcare organizations |
| gptkbp:platforms |
innovative drug discovery
|
| gptkbp:publications |
contributed to cancer research literature
|
| gptkbp:regulatoryCompliance |
gptkb:FDA
for new drug applications follows_FDA_guidelines |
| gptkbp:research |
conducted in collaboration with universities
focused on unmet medical needs |
| gptkbp:research_areas |
oncology
develops new treatment modalities targeting tumor metabolism |
| gptkbp:research_focus |
metabolic pathways in cancer
|
| gptkbp:researchAndDevelopment |
focused on cancer metabolism
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
CALA
|
| gptkbp:supplyChain |
CB-839
|
| gptkbp:supportRole |
composed of industry experts
|
| gptkbp:targets |
glutaminase
|
| gptkbp:tributaryOf |
multiple drug candidates
|
| gptkbp:vision |
to be a leader in cancer therapeutics
|
| gptkbp:website |
www.calithera.com
|